# Andrzej Maćkiewicz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrzej-mackiewicz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,112 |
| Field | Immunotherapy and Immune Responses |
| h-index | 54 |
| i10-index | 153 |
| OpenAlex ID | https://openalex.org/A5031394337 |
| ORCID iD | https://orcid.org/0000-0001-5574-6609 |
| Works | 347 |

## Researcher papers

- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)

## Researcher topics

- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gut microbiota and health](https://scholariq.org/topics/gut-microbiota-and-health/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.